Mild Elevation of N-Acetylaspartic Acid and Macrocephaly: Diagnostic Problem

Abstract

Patients with slightly increased excretion of N-acetylaspartic acid in urine, together with macrocephaly, present a dignostic dilemma for Canavan's disease. We describe a 13-year-old male patient with macrocephaly, mild developmental delay, increased signal intensity in the basal ganglia bilaterally, partial cortical blindness, and retinitis pigmentosa. Although the clinical course and magnetic resonance imaging findings did not resemble typical Canavan's disease, N-acetylaspartic acid excretion in the patient's urine was slightly elevated, 99.90 ± 4.00 μg/mg creatinine, whereas the normal control range was < 83 μg/mg creatinine. Cultured skin fibroblasts from the patient showed no aspartoacylase activity. Cloning of genomic DNA isolated from the patient's fibroblasts showed an intronic mutation, specifically deletion of -2A and -3C at the acceptor site of exon 3 and disrupting the normal splicing of the gene. A second mutation was found in exon 6, 863 A→G in aspartoacylase complementary DNA, causing a tyrosine-to-cysteine (Y288C) amino acid substitution. Expression of the mutation on exon 6 showed normal aspartoacylase activity. These data suggest that expression of the mutation may help to understand the enzyme defect in a patient with slightly increased N-acetylaspartic acid excretion. (J Child Neurol 2003;18:809—812).

Get full access to this article

View all access options for this article.

References

G l o b u s J.H. , S t r a u s s I. : P r o g r e s s i v e d e g e n e r a t i v e subcortical encephalopathy (Schilder's disease) . Arch Neurol Psychiatry 1928;20:1190—1228.

Canavan MM : Schilder's encephalitis periaxialis diffusa. Arch Neurol Psychiatry 1931;25:299—308.

Adachi M. , Torii J. , Schneck L. , Volk BW : Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Betrand type). Acta Neuropathol (Berl) 1972;20:22—31.

Adornato BT , O'Brien JS , Lampert PW , et al: Cerebral spongy degeneration of infancy. A biochemical and ultrastructural study of affected twins. Neurology 1972;22:202—210.

Matalon R. , Michals-Matalon K. : Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Front Biosci 2000;5:D307—311.

van Bogaert L. , Bertrand I. : Sur une idiotie familiale avec degenerescence sponglieuse de neuraxe (note preliminaire). Acta Neurol Belg 1949;49:572—587.

Matalon R. , Michals K. , Sebesta D. , et al: Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988;29:463—471.

Gordon N. : Canavan disease: A review of recent developments. Eur J Paediatr Neurol 2001;5:65—69.

Birnbaum SM : Amino acid acylases I and II from hog kidney. Methods Enzymol 1955;2:115—119.

10.

Birnbaum SM , Levintow L. , Kingsley RB , Greenstein JP : Specificity of amino acid acylases. J Biol Chem 1952;194:455—462.

11.

Tallan HH , Moore S. , Stein WH : N-Acetyl-L-aspartic acid in brain. J Biol Chem 1956;219:257—264.

12.

Matalon R. , Kaul R. , Casanova J. , et al: SSIEM Award. Aspartoacylase deficiency: The enzyme defect in Canavan disease. J Inherit Metab Dis 1989;12(Suppl 2):329—331.

13.

Grodd W. , Krageloh-Mann I. , Peterson D. , et al: In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan's disease) by proton spectroscopy. Lancet 1990;336:437—438.

14.

Goodman SI , Markey SP : Diagnosis of organic acidemias by gas chromatography-mass spectrometry. New York, Alan R. Liss, 1981.

15.

Kelley RI : Prenatal detection of Canavan disease by measurement of N-acetyl L-aspartate in amniotic fluid. J Inherit Metab Dis 1993 ; 16:918—919.

16.

Matalon R. , Michals K. , Kaul R. : Canavan disease: From spongy degeneration to molecular analysis. J Pediatr 1995; 127:511-517.

17.

Kaul R. , Gao GP , Michals K. , et al: Novel (cys152>arg) missense mutation in Arab patient with Canavan disease. Hum Mutat 1995;5:269—271.

18.

Matalon R. , Michals-Matalon K. : Biochemistry and molecular biology of Canavan disease. Neurochem Res 1999;24:507—513.

19.

Kaul R. , Gao GP , Aloya M. , et al: Canavan disease: Mutations among Jewish and non-Jewish patients . Am J Hum Genet 1994;55:34—41. 20. Propheta O. , Magal N. , Shohat M. , et al: A benign polymorphism in the aspartoacylase gene may cause misinterpretation of Canavan gene testing. Eur J Hum Genet 1998 ;6:635—637.

20.

Alford RL , DeMarchi JM , Richards CS : Frequency of a DNA polymorphism at position Y231 in the aspartoacylase gene and its impact on DNA-based carrier testing for Canavan disease in the Ashkenazi Jewish population. Hum Mutat 1998;Suppl 1:S161—S162.